BLRX

BioLineRx Ltd. BLRX

NasdaqMid CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $28.9M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Revenue

$1.18M

Quarter to Dec 31

Net income

$-2.03M

Quarter to Dec 31

Free cash flow

$-8.10M

Quarter to Dec 31

Top Institutional Holders

as of Q2 2026
$207.7K total
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$95.8KNew
RENAISSANCE TECHNOLOGIES LLC
$48.1KNew
CITADEL ADVISORS LLC
$45.9KNew
RHUMBLINE ADVISERS
$7.7K+5.3%
WELLS FARGO & COMPANY/MN
$6.2K+14.3%
BNP PARIBAS FINANCIAL MARKETS
$1.6K-72.2%
Banque Cantonale Vaudoise
$1.0K0.0%
Nemes Rush Group LLC
$7800.0%
UBS Group AG
$315-80.9%
NewEdge Advisors, LLC
$256New
OSAIC HOLDINGS, INC.
$810.0%
SBI Securities Co., Ltd.
$31New
DANSKE BANK A/S
$60.0%
CITIGROUP INC
$3-99.9%
See all 14 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

FY 2025
EDGAR

Net Income

FY 2025
EDGAR

EPS (Diluted)

FY 2025
EDGAR

ROIC

FY 2025
EDGAR

Free Cash Flow

FY 2025
EDGAR

Loading ratio trend…

BLRX key financials by period

Reported revenue, net income and operating margin by fiscal year, from BioLineRx Ltd.'s annual filings on SEC EDGAR.

BioLineRx Ltd. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$1.2M$-2.0M—
FY 2024$28.9M$-9.2M-70.5%
FY 2023$4.8M$-60.6M—
Source: BLRX filings on SEC EDGAR →

About BioLineRx Ltd. (BLRX): stock profile, AI score and financials

BioLineRx Ltd. (BLRX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. BLRX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $28.9m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (FY 2025), BioLineRx Ltd. reports quarterly revenue of $1.2M, net income of $-2.0M, free cash flow of $-8.1M. Top institutional holders of BLRX by reported 13-F value include SUSQUEHANNA INTERNATIONAL GROUP, LLP, RENAISSANCE TECHNOLOGIES, CITADEL ADVISORS, based on the most recent SEC filings. BLRX trades on the Nasdaq exchange and files with the SEC under CIK 1498403. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BLRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BioLineRx Ltd. directly from SEC EDGAR.

SEC EDGAR: CIK 1498403 →